DGX

Quest Diagnostics Incorporated NYSE

Healthcare ·Medical - Diagnostics & Research ·US · questdiagnostics.com

$191.50

Mkt Cap $21.2B

52w Low $164.65 55.0% of range 52w High $213.50

50d MA $199.10 200d MA $186.41

P/E (TTM) 21.7x

EV/EBITDA 11.7x

P/B 2.9x

Debt/Equity 1.0x

ROE 13.9%

P/FCF 14.2x

RSI (14) —

ATR (14) —

Beta 0.65

50d MA $199.10

200d MA $186.41

Avg Volume 1.0M

About

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Ques…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 21, 2026	AMC	2.37	2.50	+5.5%	205.04	+0.2%	-0.5%	-2.7%	-4.3%	-4.1%	-4.9%	—	—
Feb 10, 2026	AMC	2.36	2.42	+2.5%	205.35	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%	-2.2%	—
Oct 21, 2025	AMC	2.50	2.60	+4.0%	184.64	+0.1%	-1.9%	-0.8%	-1.3%	-2.4%	-3.4%	+1.6%	—
Jul 22, 2025	AMC	2.57	2.62	+1.9%	178.24	+0.8%	-4.4%	-3.6%	-5.4%	-5.8%	-5.8%	+3.1%	—
Apr 22, 2025	AMC	2.15	2.21	+2.8%	172.84	-0.0%	+0.4%	+1.8%	+0.5%	+2.2%	+3.3%	-1.9%	—
Jan 30, 2025	AMC	2.19	2.23	+1.8%	164.17	-0.1%	-0.7%	-1.0%	-0.5%	+0.4%	-0.9%	+7.8%	—
Oct 22, 2024	AMC	2.26	2.30	+1.8%	157.47	+1.5%	-0.2%	+0.3%	-1.5%	-1.0%	-1.0%	+4.1%	—
Jul 23, 2024	AMC	2.34	2.35	+0.4%	140.96	+0.7%	+2.1%	+2.3%	+3.3%	+0.8%	+1.4%	+8.4%	—
Apr 23, 2024	AMC	1.86	2.04	+9.7%	136.70	-0.5%	+0.6%	-0.9%	-1.8%	+2.0%	+1.1%	+2.4%	—
Feb 1, 2024	AMC	2.11	2.15	+1.9%	127.17	-0.6%	-1.7%	-2.7%	-0.7%	+0.2%	-0.5%	-1.5%	—
Oct 24, 2023	AMC	2.19	2.22	+1.4%	123.58	-1.4%	+1.5%	+6.2%	+3.3%	+4.7%	+5.3%	+9.7%	—
Jul 26, 2023	AMC	2.27	2.30	+1.3%	136.24	-0.2%	-1.4%	-1.3%	-0.8%	-1.2%	-1.1%	-2.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 22	Barclays	Maintains	Overweight → Overweight	—	$205.04	$205.37	+0.2%	-0.5%	-2.7%	-4.3%	-4.1%	-4.9%
Apr 22	UBS	Maintains	Neutral → Neutral	—	$205.04	$205.37	+0.2%	-0.5%	-2.7%	-4.3%	-4.1%	-4.9%
Apr 22	Truist	Maintains	Hold → Hold	—	$205.04	$205.37	+0.2%	-0.5%	-2.7%	-4.3%	-4.1%	-4.9%
Apr 22	Baird	Maintains	Neutral → Neutral	—	$205.04	$205.37	+0.2%	-0.5%	-2.7%	-4.3%	-4.1%	-4.9%
Apr 8	Evercore ISI	Maintains	In Line → In Line	—	$196.81	$196.18	-0.3%	+1.0%	+0.5%	-2.7%	-2.0%	-1.3%
Feb 12	Mizuho	Maintains	Outperform → Outperform	—	$209.32	$211.80	+1.2%	-1.2%	-1.2%	-1.8%	-2.4%	-3.3%
Feb 11	Truist	Maintains	Hold → Hold	—	$205.35	$207.04	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%
Feb 11	Jefferies	Maintains	Buy → Buy	—	$205.35	$207.04	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%
Feb 11	UBS	Maintains	Neutral → Neutral	—	$205.35	$207.04	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%
Feb 11	Evercore ISI	Maintains	In Line → In Line	—	$205.35	$207.04	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%
Feb 11	Barclays	Maintains	Overweight → Overweight	—	$205.35	$207.04	+0.8%	+1.9%	+0.7%	+0.7%	+0.1%	-0.5%
Feb 10	Citigroup	Maintains	Neutral → Neutral	—	$191.25	$194.72	+1.8%	+7.4%	+9.4%	+8.2%	+8.2%	+7.4%
Oct 27	Piper Sandler	Maintains	Neutral → Neutral	—	$182.18	$181.37	-0.4%	-1.1%	-2.1%	-4.1%	-3.5%	-3.4%
Oct 22	Barclays	Maintains	Equal Weight → Equal Weight	—	$184.64	$184.88	+0.1%	-1.9%	-0.8%	-1.3%	-2.4%	-3.4%
Oct 22	Truist	Maintains	Hold → Hold	—	$184.64	$184.88	+0.1%	-1.9%	-0.8%	-1.3%	-2.4%	-3.4%
Oct 21	Leerink Partners	Maintains	Outperform → Outperform	—	$190.41	$195.08	+2.5%	-3.0%	-4.9%	-3.8%	-4.3%	-5.3%
Oct 21	Jefferies	Maintains	Buy → Buy	—	$190.41	$195.08	+2.5%	-3.0%	-4.9%	-3.8%	-4.3%	-5.3%
Oct 17	Mizuho	Maintains	Outperform → Outperform	—	$186.82	$187.61	+0.4%	+1.4%	+1.9%	-1.2%	-3.0%	-1.9%
Oct 17	UBS	Maintains	Neutral → Neutral	—	$186.82	$187.61	+0.4%	+1.4%	+1.9%	-1.2%	-3.0%	-1.9%
Oct 8	Evercore ISI	Maintains	In Line → In Line	—	$181.89	$181.52	-0.2%	-0.5%	-0.2%	+1.2%	+0.5%	+1.9%
Oct 2	Barclays	Maintains	Equal Weight → Equal Weight	—	$182.07	$180.83	-0.7%	-0.6%	-1.5%	-2.0%	-0.1%	-0.6%
Aug 25	Baird	Downgrade	Outperform → Neutral	—	$180.23	$177.22	-1.7%	-0.9%	+0.1%	-0.3%	-0.6%	+0.8%
Jul 23	UBS	Maintains	Neutral → Neutral	—	$178.24	$179.63	+0.8%	-4.4%	-3.6%	-5.4%	-5.8%	-5.8%
Jul 23	Truist	Maintains	Hold → Hold	—	$178.24	$179.63	+0.8%	-4.4%	-3.6%	-5.4%	-5.8%	-5.8%
Jul 23	Deutsche Bank	Maintains	Hold → Hold	—	$178.24	$179.63	+0.8%	-4.4%	-3.6%	-5.4%	-5.8%	-5.8%
Jul 22	Jefferies	Maintains	Buy → Buy	—	$166.45	$170.63	+2.5%	+7.1%	+2.4%	+3.3%	+1.3%	+0.8%
Jul 18	UBS	Maintains	Neutral → Neutral	—	$168.18	$168.57	+0.2%	-0.8%	-1.0%	+6.0%	+1.4%	+2.2%
May 6	JP Morgan	Maintains	Neutral → Neutral	—	$177.57	$177.15	-0.2%	-0.8%	-0.6%	-0.9%	-0.3%	-0.9%
Apr 28	Piper Sandler	Maintains	Neutral → Neutral	—	$173.76	$174.68	+0.5%	+1.7%	+2.7%	+2.6%	+2.0%	+2.4%
Apr 23	Truist	Maintains	Hold → Hold	—	$172.84	$172.77	-0.0%	+0.4%	+1.8%	+0.5%	+2.2%	+3.3%
Apr 23	Evercore ISI	Maintains	In Line → In Line	—	$172.84	$172.77	-0.0%	+0.4%	+1.8%	+0.5%	+2.2%	+3.3%
Apr 23	Barclays	Maintains	Equal Weight → Equal Weight	—	$172.84	$172.77	-0.0%	+0.4%	+1.8%	+0.5%	+2.2%	+3.3%
Apr 23	Baird	Maintains	Outperform → Outperform	—	$172.84	$172.77	-0.0%	+0.4%	+1.8%	+0.5%	+2.2%	+3.3%
Apr 9	Mizuho	Maintains	Outperform → Outperform	—	$159.80	$158.15	-1.0%	+2.7%	+2.5%	+2.6%	+5.1%	+4.6%
Mar 20	Baird	Maintains	Outperform → Outperform	—	$168.01	$167.80	-0.1%	-0.9%	-0.5%	-0.4%	-1.4%	-0.8%
Mar 4	Citigroup	Downgrade	Buy → Neutral	—	$176.95	$175.79	-0.7%	-1.1%	-2.8%	-3.0%	-0.8%	-2.2%
Feb 4	JP Morgan	Maintains	Neutral → Neutral	—	$162.47	$162.28	-0.1%	+0.5%	+1.5%	+0.1%	+0.1%	+1.7%
Feb 3	Piper Sandler	Maintains	Neutral → Neutral	—	$163.10	$161.84	-0.8%	-0.4%	+0.2%	+1.1%	-0.3%	-0.3%
Feb 3	Mizuho	Maintains	Outperform → Outperform	—	$163.10	$161.84	-0.8%	-0.4%	+0.2%	+1.1%	-0.3%	-0.3%
Feb 3	UBS	Maintains	Neutral → Neutral	—	$163.10	$161.84	-0.8%	-0.4%	+0.2%	+1.1%	-0.3%	-0.3%
Jan 31	Barclays	Maintains	Equal Weight → Equal Weight	—	$164.17	$163.94	-0.1%	-0.7%	-1.0%	-0.5%	+0.4%	-0.9%
Jan 31	Truist	Maintains	Hold → Hold	—	$164.17	$163.94	-0.1%	-0.7%	-1.0%	-0.5%	+0.4%	-0.9%
Jan 6	Leerink Partners	Upgrade	Market Perform → Outperform	—	$151.92	$152.46	+0.4%	+0.2%	+1.1%	+1.4%	-0.1%	+1.4%
Dec 23	Mizuho	Maintains	Outperform → Outperform	—	$153.10	$152.33	-0.5%	-0.1%	+0.2%	-0.1%	-0.3%	-1.4%
Dec 17	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$152.65	$153.19	+0.4%	+1.9%	-0.9%	-0.7%	+0.3%	+0.2%
Dec 13	BofA Securities	Maintains	Buy → Buy	—	$156.07	$156.10	+0.0%	-0.7%	-2.2%	-0.4%	-3.1%	-2.9%
Oct 28	Piper Sandler	Maintains	Neutral → Neutral	—	$155.04	$155.68	+0.4%	+0.6%	+0.6%	+0.6%	-0.1%	+0.2%
Oct 24	Mizuho	Maintains	Outperform → Outperform	—	$157.12	$157.59	+0.3%	+0.6%	-1.3%	-0.8%	-0.7%	-0.8%
Oct 23	Baird	Upgrade	Neutral → Outperform	—	$157.47	$159.84	+1.5%	-0.2%	+0.3%	-1.5%	-1.0%	-1.0%
Oct 23	Citigroup	Maintains	Buy → Buy	—	$157.47	$159.84	+1.5%	-0.2%	+0.3%	-1.5%	-1.0%	-1.0%

Recent Filings

8-K

Quest Diagnostics Inc. -- 8-K Filing

Quest Diagnostics reported over 9% organic revenue growth and 13% adjusted EPS growth in Q1 2026, demonstrating strong execution and expanding profitability despite a competitive diagnostic services market.

Apr 21

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Leadership transitions can signal strategic shifts or governance changes; investors should monitor whether this executive change strengthens management quality and operational execution to justify current valuation multiples.

Mar 12

8-K · 1.01 !! High

Insight Molecular Diagnostics Inc. -- 8-K 1.01: Material Agreement

Insight Molecular Diagnostics partnered with Quest Diagnostics through a specimen collection agreement, potentially expanding IMDX's diagnostic reach and revenue streams via Quest's extensive laboratory network.

Feb 26

8-K · 8.01 !! High

Quest Diagnostics Inc. -- 8-K 8.01: Material Event / Announcement

Quest Diagnostics increased its quarterly dividend by 7.5%, signaling management confidence in stable cash flows and returning more capital to shareholders.

Feb 10

Data updated apr 25, 2026 5:06am · Source: massive.com